Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.
NEW BRUNSWICK, NJ – Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a U.S. subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of regenerative medicine products, and Rutgers University–New Brunswick’s School of Engineering today announced a collaboration to launch a graduate-level course, “Integrative Molecular and Cellular ...
After three years of operations leadership for Hitachi Chemical Advanced Therapeutics Solutions (HCATS), William (Bill) Monteith will be leaving HCATS with transition expected to complete by November 2018. Brian Hanifin will fill the role of Interim Head of Technical Operations for HCATS. Brian has 25+ years of extensive pharmaceutical experience leading internal company plants. He has been an ...
March 19, 2018 - Hitachi Chemical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Hisashi Maruyama; hereinafter “Hitachi Chemical”) announces the signing of an agreement with Daiichi Sankyo Co., Ltd. (Head Office: Chuo-ku, Tokyo; hereinafter “Daiichi Sankyo”) for clinical manufacturing*1 of Regenerative Medicine developed by Daiichi Sankyo for the Japanese market. Hitachi Chemical ...
Tokyo, Japan, March 13, 2018—SanBio Group and Hitachi Chemical Co., Ltd. (Hitachi Chemical) jointly announced today that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LCC (HCATS; formerly PCT Cell Therapy Services, LLC), Hitachi Chemical’s U.S. subsidiary that engages in contract manufacturing and development of regenerative medicine products1, they will manufacture ...
We at Hitachi Chemical Advanced Therapeutics Solutions, LLC are excited to announce that construction on additional PCT GMP manufacturing infrastructure and cleanroom capacity has begun at our newly-leased 49,700 square foot facility in Allendale, New Jersey (“75 Commerce”) in addition to upgrades to our existing facility at 4 Pearl Court, Allendale (“4 Pearl Court”). The upgrades will allow us ...
Leiden, The Netherlands, and Munich, Germany, October 19, 2017 - DCPrime BV, a clinical stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, report today that they have entered into a strategic manufacturing agreement. The collaboration involves clinical batch ...
Yokohama, Japan, October 19, 2017: Hitachi Chemical Co., Ltd. (HCC), a global service provider for the cell therapy industry through its PCT development and manufacturing service platform, today announced the completion of construction and opening of its Yokohama, Japan facility on October 11. This facility, as well as the existing two U.S. PCT facilities, will share the same global PCT service ...
Allendale, NJ, USA, October 10, 2017 Today, Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a global service provider for the cell therapy industry through its PCT development and manufacturing platform, announced the planned expansion of its PCT service platform through the addition of GMP manufacturing infrastructure and cleanroom capacity in Allendale, NJ. The expansion includes ...
Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with rare diseases of high unmet medical need announces today that it has entered a new clinical manufacturing services agreement with PCT Cell Therapy Services, LLC (“PCT”), a Hitachi Group Company. PCT is a leading provider of contract services ...